Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ohara Pharmaceutical Company has received Japanese development and commercialisation rights from EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, for EUSA Pharma's oncology therapy Erwinase.
Subscribe to our email newsletter
Erwinase is an L-asparaginase derived from Erwinia chrysanthemi, used for the treatment of acute lymphoblastic leukemia in combination with other anti-neoplastic agents.
Erwinase is currently approved for use in Canada and in a number of countries in Europe, the Middle East and Asia, and is undergoing registration procedures in several other territories.
As per the terms of the agreement, Ohara Pharma is expected to take up the responsibility of any late-stage development required by the Japanese authorities while EUSA Pharma is expected to receive an upfront fee and royalties on future sales.
Bryan Morton, president and CEO of EUSA Pharma, said: “This agreement represents an important milestone for EUSA as it extends the reach of our partnership network to the Japanese market. Our new partnership with Ohara extends the reach of our commercialisation capabilities, which now cover all the pharmaceutical markets.”
Seiji Ohara, president and CEO of Ohara Pharma, said: “Erwinase is an ideal fit with Ohara’s portfolio of oncology and orphan drugs, and continues the transition of our business towards new therapeutics. We look forward to working with the Japanese health authorities and opinion leaders to make this therapy available to patients throughout Japan.”